Statins in Non-alcoholic Steatohepatitis

Torres-Peña, José D.; Martín-Piedra, Laura; Fuentes-Jiménez, Francisco

doi:10.3389/fcvm.2021.777131

Cited by 17 publications

(11 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statins play a well-established role in the primary and secondary prevention of CVD and are safe among patients with chronic liver disease such as NAFLD, including those with mild baseline elevation in transaminases (< 3 × upper limit of normal [ULN]) or compensated cirrhosis [ 65 – 71 ]. Similarly, there is evidence that statins may attenuate NASH and reduce the risk of liver fibrosis [ 72 ].…”

Section: Introductionmentioning

confidence: 99%

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

Martin

Lang

Goeser

et al. 2022

Curr Atheroscler Rep

View full text Add to dashboard Cite

Purpose of Review Patients with non-alcoholic fatty liver disease (NAFLD), often considered as the hepatic manifestation of the metabolic syndrome, represent a population at high cardiovascular risk and frequently suffer from atherogenic dyslipidemia. This article reviews the pathogenic interrelationship between NAFLD and dyslipidemia, elucidates underlying pathophysiological mechanisms and focuses on management approaches for dyslipidemic patients with NAFLD. Recent Findings Atherogenic dyslipidemia in patients with NAFLD results from hepatic and peripheral insulin resistance along with associated alterations of hepatic glucose and lipoprotein metabolism, gut dysbiosis, and genetic factors. Summary Since atherogenic dyslipidemia and NAFLD share a bi-directional relationship and are both major driving forces of atherosclerotic cardiovascular disease (ASCVD) development, early detection and adequate treatment are warranted. Thus, integrative screening and management programs are urgently needed. A stepwise approach for dyslipidemic patients with NAFLD includes (i) characterization of dyslipidemia phenotype, (ii) individual risk stratification, (iii) definition of treatment targets, (iv) lifestyle modification, and (v) pharmacotherapy if indicated.

show abstract

Section: Introductionmentioning

confidence: 99%

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

Martin

Lang

Goeser

et al. 2022

Curr Atheroscler Rep

View full text Add to dashboard Cite

show abstract

“…Statins, hydroxymethylglutaryl-CoA reductase inhibitors, are widely used in various chronic diseases including NAFLD ( 118 , 119 ). In a multicenter cohort of 1,201 subjects, statins improved histological liver damage in individuals with NAFLD/NASH in a dose-dependent manner and protected against steatosis, steatohepatitis, and fibrosis progression ( 120 ).…”

Section: Treatments For Nafld and Their Impact On Hfpefmentioning

confidence: 99%

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Yang

Tian²,

Zhang³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors and/or by boosting systemic inflammation, releasing other secretory factors, and having an expansion of epicardial adipose tissue (EAT). Therefore, the treatments of NAFLD may also affect the development and prognosis of HFpEF. However, no specific drugs for NAFLD have been approved by the Food and Drug Administration (FDA) and some non-specific treatments for NAFLD are applied in the clinic. Currently, the treatments of NAFLD can be divided into non-pharmacological and pharmacological treatments. Non-pharmacological treatments mainly include dietary intervention, weight loss by exercise, caloric restriction, and bariatric surgery. Pharmacological treatments mainly include administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and metformin. This review will mainly focus on analyzing how these treatments may affect the development and prognosis of HFpEF.

show abstract

“…There are few effective drugs for treatment and prevention of NAFLD/NASH. Pioglitazone may be effective in advanced NASH patients or associated with type 2 diabetes, but reliable clinical data are lacking (Shaaban et al, 2022); vitamin E and D have some efficacy, but the safety of long-term use is unclear and the course of treatment is inconclusive (Perumpail et al, 2018;Ravaioli et al, 2022); statins can reduce serum LDL levels and prevent cardiovascular complications, but do not address the progression of liver disease (Torres-Peña et al, 2021). Some Intestinal barrier disrupted by gut dysbiosis facilitates bacterial endotoxins to liver and exacerbates inflammatory process and fat accumulation in the pathogenesis of NAFLD.…”

Section: Novel Strategy For Nafld Treatment Based On Gut Microbiotamentioning

confidence: 99%

Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications

Fang

Yu²,

Li³

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing recently and has become one of the most common clinical liver diseases. Since the pathogenesis of NAFLD has not been completely elucidated, few effective therapeutic drugs are available. As the “second genome” of human body, gut microbiota plays an important role in the digestion, absorption and metabolism of food and drugs. Gut microbiota can act as an important driver to advance the occurrence and development of NAFLD, and to accelerate its progression to cirrhosis and hepatocellular carcinoma. Growing evidence has demonstrated that gut microbiota and its metabolites directly affect intestinal morphology and immune response, resulting in the abnormal activation of inflammation and intestinal endotoxemia; gut dysbiosis also causes dysfunction of gut-liver axis via alteration of bile acid metabolism pathway. Because of its composition diversity and disease-specific expression characteristics, gut microbiota holds strong promise as novel biomarkers and therapeutic targets for NAFLD. Intervening intestinal microbiota, such as antibiotic/probiotic treatment and fecal transplantation, has been a novel strategy for preventing and treating NAFLD. In this article, we have reviewed the emerging functions and association of gut bacterial components in different stages of NAFLD progression and discussed its potential implications in NAFLD diagnosis and therapy.

show abstract

Statins in Non-alcoholic Steatohepatitis

Cited by 17 publications

References 65 publications

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications

Contact Info

Product

Resources

About